Atara Biotherapeutics Files IND to Advance Lupus Treatment

Atara Biotherapeutics (Nasdaq: ATRA) has submitted an Investigational New Drug (IND) application to
the FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus
(SLE) with kidney involvement (lupus nephritis). Despite therapeutic advances, there remains a high
unmet need for effective treatments for lupus nephritis.

Rajani Dinavahi, Chief Medical Officer at Atara, said, “We are dedicated to advancing medical
breakthroughs with innovative cell therapies that truly make a difference. We look forward to working
with the FDA to initiate this study and advance ATA3219 into the clinic to potentially bring a new
disease-modifying option for patients suffering from this chronic disease.”
Highlights

Atara’s ATA3219 IND submission includes robust in vitro data reflecting the CD19 antigen-specific
functional activity of ATA3219 and CAR-mediated activity against B cells from SLE patients. ATA3219 led
to near-complete CD19-specific B-cell depletion compared to controls.

ATA3219 combines the natural biology of unedited T cells with the benefits of an allogeneic therapy.
Lupus nephritis is a serious and most common complication of SLE, a chronic multisystem autoimmune
disease. SLE affects around 200,000 people in the United States, and up to 60% of adult patients with
SLE develop renal disease during the course of their illness.
About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for
difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients within
days. With cutting-edge science and differentiated approach, Atara is the first company in the world to
receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-
Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis
of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in
addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of
hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern
California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.